Physician profile
Daniel Warner
NPI 1285608299
$15,481.78
in general payments reported to CMS, 2019-2025
26 companies · $1,481 in 2025
The $1,481 reported for 2025 was more than what 90% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $7,893 · 2020: $1,432 · 2021: $1,463 · 2022: $1,210 · 2023: $906 · 2024: $1,096 · 2025: $1,481.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,091 · Consulting Fee: $375 · Education: $17.38.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,091.12 |
| Consulting Fee | $375.00 |
| Education | $17.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Viiv Healthcare Company | $9,471.93 | 2019-2025 | Dovato, Apretude, Cabenuva |
| Janssen Biotech, INC. | $1,053.24 | 2019-2023 | Symtuza |
| Merck Sharp & Dohme LLC | $1,022.92 | 2019-2025 | Pifeltro, Delstrigo, Dificid |
| Gilead Sciences, INC. | $980.11 | 2019-2025 | |
| Theratechnologies INC. | $766.41 | 2019-2025 | Egrifta, Trogarzo |
| Novo Nordisk INC | $471.44 | 2019-2024 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals Lp | $283.03 | 2019-2022 | |
| Abbvie INC. | $261.62 | 2019-2025 | |
| Insmed, INC. | $228.61 | 2021-2025 | Arikayce, Brinsupri |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $188.22 | 2019-2023 | Xifaxan |
| Janssen Products, Lp | $159.00 | 2021-2022 | |
| Lilly USA, LLC | $125.81 | 2020-2024 | Mounjaro, Zepbound |
| Emd Serono, INC. | $103.57 | 2019-2025 | |
| Amgen INC. | $59.33 | 2019-2023 | Repatha, Otezla |
| Exact Sciences Corporation | $54.91 | 2025 | The Cologuard Plus Collection Kit |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Napo Pharmaceuticals INC | $48.34 | 2019-2025 | Mytesi |
| Janssen Pharmaceuticals, INC | $44.19 | 2020-2021 | |
| Glaxosmithkline, LLC. | $23.58 | 2019 | |
| Smith+Nephew, INC. | $19.32 | 2020 | |
| Almatica Pharma LLC | $19.22 | 2024 | Teriparatide |
| Boehringer Ingelheim Pharmaceuticals, INC. | $18.90 | 2020 | |
| Astellas Pharma US INC | $18.89 | 2024 | Veozah |
| Allergan, INC. | $18.72 | 2019 | |
| Octapharma USA, INC. | $14.72 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $14.68 | 2025 | |
| Aytu Biopharma, INC. | $11.07 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Warner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.